{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:47:54Z","timestamp":1790729274299,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jtha.2022.12.017","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T15:24:24Z","timestamp":1674660264000},"page":"800-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Race, ethnicity, F8 variants, and inhibitor risk: analysis of the \u201cMy Life Our Future\u201d hemophilia A database"],"prefix":"10.1016","volume":"21","author":[{"given":"Anwar E.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen P.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2022.12.017_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/ng1193-236","article-title":"Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A","volume":"5","author":"Lakich","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2022.12.017_bib2","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/hmg\/2.11.1773","article-title":"Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions","volume":"2","author":"Naylor","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jtha.2022.12.017_bib3","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1182\/blood-2006-06-026104","article-title":"A\u00a0sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels","volume":"109","author":"Viel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/bloodadvances.2016002923","article-title":"Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative","volume":"1","author":"Johnsen","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.12.017_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/hae.13506","article-title":"My Life Our Future programme. Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project","volume":"24","author":"Konkle","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1538-7836.2004.00802.x","article-title":"Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX","volume":"2","author":"Lollar","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/hae.12563","article-title":"The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison","volume":"21","author":"Hay","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib8","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.13888","article-title":"Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis","volume":"16","author":"Peyvandi","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib10","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.017_bib11","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2022.12.017_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jtha.2022.12.017_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hae.13616","article-title":"Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study","volume":"25","author":"Scott","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","article-title":"Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity","volume":"18","author":"Miller","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib17","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2516.2008.01694.x","article-title":"Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations","volume":"14","author":"Boekhorst","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","article-title":"Inhibitors occur more frequently in African-American and Latino haemophiliacs","volume":"4","author":"Aledort","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1365-2516.2009.02058.x","article-title":"Risk factors for inhibitor formation in haemophilia: a prevalent case-control study","volume":"15","author":"Ragni","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2516.2010.02429.x","article-title":"Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?","volume":"17","author":"Callaghan","year":"2011","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.jtha.2022.12.017_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-09-599365","article-title":"Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators. Factor VIII gene variants and inhibitor risk in African American hemophilia A patients","volume":"126","author":"Gunasekera","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtha.2022.12.017_bib23","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/j.1365-2516.2011.02739.x","article-title":"Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database","volume":"18","author":"Carpenter","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1365-2516.2011.02509.x","article-title":"Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A","volume":"17","author":"Leissinger","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.V110.11.1163.1163","article-title":"The role of race and ethnicity in the clinical outcomes of severe hemophilia A patients with inhibitors","volume":"110","author":"Kruse-Jarres","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib26","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa075760","article-title":"Inhibitors of factor VIII in black patients with hemophilia","volume":"360","author":"Viel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.017_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003066","article-title":"Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia A: a computational assessment","volume":"9","author":"Pandey","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.jtha.2022.12.017_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2002-05-1369","article-title":"CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A","volume":"101","author":"Jacquemin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/j.1538-7836.2007.02762.x","article-title":"T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide","volume":"5","author":"James","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2516.2008.01905.x","article-title":"HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P","volume":"16","author":"Ettinger","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1538-7836.2011.04202.x","article-title":"T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site","volume":"9","author":"James","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib32","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/jth.13144","article-title":"Complexity and diversity of F8 genetic variations in the 1000 genomes","volume":"13","author":"Li","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib33","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3270","article-title":"PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A","volume":"19","author":"Pandey","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2022.12.017_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2013-12-530113","article-title":"The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics","volume":"125","author":"Sauna","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib35","first-page":"PB192","article-title":"Hemophilia A subjects with an intron-22 inversion mutation show robust T-cell responses to epitopes in both the FVIII heavy and light chain","author":"Gunasekera","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib36","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/hmg\/4.7.1217","article-title":"Investigation of the factor VIII intron 22 repeated region (int22h) and the associated inversion junctions","volume":"4","author":"Naylor","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jtha.2022.12.017_bib37","first-page":"66","article-title":"A\u00a01.6-Mb contig of yeast artificial chromosomes around the human factor VIII gene reveals three regions homologous to probes for the DXS115 locus and two for the DXYS64 locus","volume":"51","author":"Freije","year":"1992","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jtha.2022.12.017_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0888-7543(05)80155-7","article-title":"Evidence for a third transcript from the human factor VIII gene","volume":"14","author":"Levinson","year":"1992","journal-title":"Genomics"},{"key":"10.1016\/j.jtha.2022.12.017_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/793502","article-title":"Detection of intracellular Factor VIII protein in peripheral blood mononuclear cells by flow cytometry","author":"Pandey","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jtha.2022.12.017_bib40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-0037-1615873","article-title":"CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects","volume":"82","author":"Reding","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellimm.2015.11.001","article-title":"Hunting down factor VIII in the immunopeptidome","volume":"301","author":"Hartholt","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2022.12.017_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cellimm.2015.09.007","article-title":"T\u00a0cell response to FVIII","volume":"301","author":"Jacquemin","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2022.12.017_bib43","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/blood-2011-08-374645","article-title":"CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1\u22171501 mice","volume":"119","author":"Steinitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hae.12004","article-title":"Berntorp E, Hemophilia Inhibitor Genetics Study Combined Cohort. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort","volume":"19","author":"Schwarz","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/hae.12436","article-title":"Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients","volume":"20","author":"Lochan","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib46","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood.V86.6.2206.bloodjournal8662206","article-title":"Factor VIII gene inversions in severe hemophilia A: results of an international consortium study","volume":"86","author":"Antonarakis","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib47","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1055\/s-0038-1649954","article-title":"Haemophilia A: mutation type determines risk of inhibitor formation","volume":"74","author":"Schwaab","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib48","article-title":"HLA variants and inhibitor development in hemophilia A: a retrospective case-controlled study using the ATHNdataset","volume":"8","author":"McGill","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jtha.2022.12.017_bib49","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/jth.15805","article-title":"Results of genetic analysis of 11 314 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States","volume":"20","author":"Johnsen","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2516.2010.02306.x","article-title":"Mild haemophilia: a disease with many faces and many unexpected pitfalls","volume":"16","author":"Peerlinck","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.017_bib51","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib52","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jth.12990","article-title":"Inhibitor development and mortality in non-severe hemophilia A","volume":"13","author":"Eckhardt","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib53","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/j.1538-7836.2010.04013.x","article-title":"In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study","volume":"8","author":"Kempton","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib54","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1002\/ajh.26011","article-title":"Management of inhibitors in persons with non-severe hemophilia A in the United States","volume":"96","author":"Lim","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2022.12.017_bib55","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.017_bib56","series-title":"Applied logistic regression","author":"Hosmer","year":"2013"},{"key":"10.1016\/j.jtha.2022.12.017_bib57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12370","article-title":"Methods for individualising factor VIII dosing in prophylaxis","volume":"76","author":"Ar","year":"2014","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.jtha.2022.12.017_bib58","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.017_bib59","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1160\/TH15-08-0692","article-title":"Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors","volume":"115","author":"van den Berg","year":"2016","journal-title":"Thromb Haemost"}],"updated-by":[{"DOI":"10.1016\/j.jtha.2023.04.017","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622182577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622182577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:25:00Z","timestamp":1711931100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622182577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1538783622182577"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2022.12.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Race, ethnicity, F8 variants, and inhibitor risk: analysis of the \u201cMy Life Our Future\u201d hemophilia A database","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2022.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}